Side-effects have been considered as the limitation of the chemotherapy agents’ administration and life quality in patients with ovarian cancers. In order to explore the influence of the chemotherapy agents commonly used in ovarian cancer patients on the blood glucose metabolism in rat models, we conducted this study which simulated the conditions of clinical protocols.
Eighty clean-grade female Wistar rats were randomized into 8 groups: Group 1 (Negative control), Group 1′ (Dexamethasone), Group 2 (Carboplatin), Group 2′ (Carboplatin-plus-dexamethasone), Group 3 (Paclitaxel), Group 3′ (Paclitaxel-plus-dexamethasone), Group 4 (Combined therapy), Group 4′ (Combined-therapy-plus-dexamethasone). On day 0, 4, 7 and 14, after fasted for 12 h, the rats in all groups underwent a glucose load and their blood glucose, glucagon and insulin levels were measured.
The glucose levels in group 2, 3 and 4 at 1 h after the loading on day 4 significantly increased (P = 0.190, 0.008 and 0.025, respectively). The glucagon levels in group 3 and 4 showed a similar trend and the increase was not suppressed by the glucose loading (P < 0.001). A significant decrease of insulin levels in group 2, 3 and 4 were observed on day 14 after treatment (P = 0.043, 0.019 and 0.019, respectively). The change of HOMA2 %B, an index reflects the ability of insulin secretion was negatively corresponded to the glucose levels, and the trends of HOMA2 IR, an index shows insulin resistance, were positively correlated to the glucose levels. The application of dexamethasone could reduce the degree of increased glucose levels significantly in group 2, 3 and 4. There were no differences in overall survival between the 8 groups. Edema in the stroma of pancreases was observed in group 3, 3′, 4 and 4′ on day 4 after treatment (P = 0.002, 0.002, 0.000 and 0.000 respectively) and lasted until day 14.
Carboplatin and paclitaxel administration could cause a transient hyperglycemia in rats. This effect might occur by the combination of glucagon accumulation due to the decrease in islet cell secretion. The additional dexamethasone in the combination protocol of carboplatin and paclitaxel seemed to reduce the impaired blood glucose metabolism.
Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res. 2001;7(12):3942–9. PubMed
Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004;100(6):1179–85. CrossRefPubMed
Wang CH, Cui H, Li X, Wang ZQ, Wei LH, Ji XM. Study on factors inducing diabetes mellitus after chemotherapy. Clin. J Obstet Gynecol. 2004;5(6):416–9.
Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol. 1999;26(5 Suppl 17):14–8. PubMed
Friedland DM, Dakhil S, Hollen C, Gregurich MA, Asmar L. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer. Cancer Investig. 2004;22(3):374–82. CrossRef
Nan DN, Fernandez-Ayala M, Vega Villegas ME, Garcia-Castano A, Rivera F, Lopez-Brea M, et al. Diabetes mellitus following cisplatin treatment. Acta oncologica (Stockholm, Sweden). 2003;42(1):75–8. CrossRef
Schmidt J, Lewandrowsi K, Warshaw AL, Compton CC, Rattner DW. Morphometric characteristics and homogeneity of a new model of acute pancreatitis in the rat. Int J Pancreatol. 1992;12(1):41–51. PubMed
Dansuntornwong B, Chanprasertyothin S, Jongjaroenprasert W, Ngarmukos C, Bunnag P, Puavilai G, et al. The relation between parameters from homeostasis model assessment and glycemic control in type 2 diabetes. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2007;90(11):2284–90. PubMed
HOMA-2 calculator www.dtu.ox.ac.uk/homacalculator/. Accessed 15 Mar 2017.
Ozols RF. Update of the NCCN ovarian cancer practice guidelines. Oncology (Williston Park, NY). 1997;11(11a):95–105.
Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, et al. Eastern cooperative oncology group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998;16(5):1669–76. CrossRefPubMed
- Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II